Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073008 · ClinicalTrials.gov registry record · Phase 2
A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
NCT00073008 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 131 participants.
The verdict
NCT00073008, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
Study Summary
This study was designed to evaluate and compare the efficacy of two dose schedules of an oral investigational drug for the treatment of advanced or metastatic non-small cell lung cancer.
Interventions
- DRUG GW572016 (lapatinib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2003-11 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073008
The ClinicalTrials.gov registry entry for NCT00073008 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GW572016 (lapatinib) is the first listed.
NCT00073008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00073008 about?
NCT00073008 is a clinical study titled "A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer". This study was designed to evaluate and compare the efficacy of two dose schedules of an oral investigational drug for the treatment of advanced or metastatic non-small cell lung cancer.
What is the current status of trial NCT00073008?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2003-11. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00073008?
The interventions under investigation include: GW572016 (lapatinib) (DRUG).
Who is sponsoring clinical trial NCT00073008?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.